Skip to Content

Join the 'Renal Cell Carcinoma' group to help and get support from people like you.

Renal Cell Carcinoma News

Related terms: Adenocarcinoma of renal cells, Cancer, Hypernephroma, Cancer, Kidney, Cancer, Renal, Cancer, Renal Cell Carcinoma, Hypernephroma, Kidney Cancer, Renal Cancer

Survival Continues to Improve for Most Cancers

Posted 31 Mar 2017 by Drugs.com

FRIDAY, March 31, 2017 – Overall cancer death rates in the United States continue to fall, but racial gaps persist, a new report says. Death rates fell between 2010 and 2014 for 11 of the 16 most common cancers in men and for 13 of the most common types in women, including lung, colon, prostate and breast cancers. However, death rates rose for cancers of the liver, pancreas and brain in men and for the liver and uterus in women. And improvements in cancer survival weren't equal for all Americans. "While this report found that five-year survival for most types of cancer improved among both blacks and whites over the past several decades, racial disparities for many common cancers have persisted, and they may have increased for prostate cancer and female breast cancer," said Dr. Lynne Penberthy. She's associate director of the U.S. National Cancer Institute's Surveillance Research ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Brain Tumor, Melanoma, Skin Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Osteosarcoma, Small Cell Lung Cancer, Breast Cancer - Adjuvant, Bladder Cancer, Cervical Cancer, Melanoma - Metastatic

Another Study Ties Obesity to Certain Cancers

Posted 1 Mar 2017 by Drugs.com

WEDNESDAY, March 1, 2017 – Carrying extra weight increases the risk of a number of cancers, a new review reports. Additional pounds appear to particularly influence the risk of cancers related to the digestive organs or those driven by hormonal abnormalities, according to the review's European authors. The evidence is so strong at this point that important organizations such as the International Agency for Research on Cancer describe "excess body weight as an important cause of cancers," said Susan Gapstur. She's vice president of epidemiology at the American Cancer Society. The new evidence review was led by Maria Kyrgiou, of Imperial College London's Department of Surgery and Cancer. The review found that a jump in a person's body mass index (BMI) of 5 was associated with a higher cancer risk in the esophagus, bone marrow, biliary tract system, pancreas and kidneys. BMI is a rough ... Read more

Related support groups: Obesity, Cancer, Weight Loss, Breast Cancer, Prostate Cancer, Renal Cell Carcinoma, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Stomach Cancer, Gastric Cancer, Wilms' Tumor, Solid Tumors, Giant Cell Tumor of Bone, Neoplasm of Bone, Insulinoma, Peritoneal Cancer

Toxins in Your Fast-Food Packaging?

Posted 1 Feb 2017 by Drugs.com

WEDNESDAY, Feb. 1, 2017 – Many grease-resistant fast-food wrappers and boxes contain potentially harmful chemicals that can leach into food, a new study contends. Testing on more than 400 samples from restaurants nationwide revealed that nearly half of fast-food wrappers and one out of five paperboard food boxes contained detectable levels of fluorine, said lead researcher Laurel Schaider. She's an environmental chemist at the Silent Spring Institute in Newton, Mass. Previous studies have linked some fluorinated chemicals such as perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) to kidney and testicular cancer, low birth weight, thyroid disease, decreased sperm quality, pregnancy-induced high blood pressure, and immune system problems in children, the study authors said in background notes. Major U.S. manufacturers voluntarily phased out PFOA and PFOS for most uses ... Read more

Related support groups: High Blood Pressure, Hypertension, Thyroid Disease, Renal Cell Carcinoma, Immunosuppression, Poisoning, Premature Labor, Toxic Reactions Incl Drug and Substance Abuse, Testicular Cancer, Labor Pain, Hypertensive Heart Disease, Prematurity/Underweight in Infancy

Kidney Cancer Drug Shows Promise in Early Trial

Posted 30 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 30, 2016 – An experimental drug may show promise in treating kidney cancer, researchers say. The drug CB-839 is the first to target an enzyme that cancer cells require to stay alive, researchers said. This stage 1 clinical trial found that the drug was effective in most patients with advanced kidney cancer when used in combination with another cancer drug called everolimus (Afinitor, Zortress). In the 15 patients in the study, the dual treatment controlled tumors in 93 percent of the patients, who had either clear cell or papillary renal cell cancer. Tumors shrank by more than 30 percent in one patient, were stable in 13 patients, and grew by more than 20 percent in one patient. Clear cell is the most common form of kidney cancer, accounting for 75 percent of cases, the researchers said. All 12 patients with this type of kidney cancer had their disease controlled. ... Read more

Related support groups: Renal Failure, Renal Cell Carcinoma, Chronic Kidney Disease, Afinitor, Peritoneal dialysis, Everolimus, Wilms' Tumor, Renal Osteodystrophy, Zortress, Afinitor Disperz, Hyperphosphatemia of Renal Failure

Freeze Therapy: An Alternative to Breast Cancer Surgery?

Posted 12 Oct 2016 by Drugs.com

TUESDAY, Oct. 11, 2016 – A freezing technique known as cryoablation might be a viable alternative to lumpectomy for treating small, early stage breast cancers, researchers report. In the small study of 86 patients, "cryoablation was shown to successfully [treat] the majority of small breast cancers with few side effects or complications," said study co-author Dr. Deanna Attai. She's an assistant clinical professor of surgery at the University of California, Los Angeles David Geffen School of Medicine. Using this minimally invasive approach to destroy cancer cells, there should be little to no change in the appearance of the breast, said Attai, immediate past president of the American Society of Breast Surgeons. The major risk, Attai said, is not killing all the cancerous cells. Another surgeon noted that although further research is still needed, cryoablation appears to be "a potential ... Read more

Related support groups: Cancer, Breast Cancer, Lung Cancer, Renal Cell Carcinoma, Breast Cancer - Adjuvant, Breast Cancer, Prevention

Do Overweight People Fare Better Than Others With Kidney Cancer?

Posted 7 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 7, 2016 – Obesity is a risk factor for kidney cancer. Yet, obese people with advanced kidney cancer seem to live longer than normal-weight or underweight patients, a new study finds. In one database of nearly 2,000 patients with advanced kidney cancer, those who were obese or overweight survived nearly 26 months, compared to 17 months for those of normal weight. And, overweight patients were 16 percent less likely to die during the study period, the researchers reported. Similar findings were uncovered using three other databases. The records of more than 7,000 kidney cancer patients were reviewed by the study authors. "Paradoxically, when overweight individuals developed kidney cancer, especially in its advanced, metastatic form, their disease progressed more slowly and they lived longer than their normal-weight counterparts," said lead researcher Dr. Toni Choueiri. ... Read more

Related support groups: Obesity, Cancer, Renal Failure, Renal Cell Carcinoma, Chronic Kidney Disease, Wilms' Tumor, Urinary Tract Tumors, Urinary Tract Cancer

Excess Weight Tied to Higher Risk for Many Cancers, Experts Say

Posted 25 Aug 2016 by Drugs.com

WEDNESDAY, Aug. 23, 2016 – Staying slim throughout your life might lower your risk of developing at least eight types of cancer, an international cancer research group says. Those include cancers of the stomach, liver, gallbladder, pancreas, ovary and thyroid. The list also includes a form of brain cancer known as meningioma, as well as a type of blood cancer called multiple myeloma. What's more, the latest research builds on the findings of an earlier review by the International Agency for Research on Cancer (IARC), which is part of the World Health Organization. That research found that those who avoid gaining weight can curtail their risk for developing five other types of cancer, including cancer of the colon, esophagus, kidney, breast and uterus. "The review certainly concluded crystal clear, as you say, that obesity causes cancer," noted Dr. Graham Colditz, who chaired the IARC ... Read more

Related support groups: Obesity, Cancer, Breast Cancer, Renal Cell Carcinoma, Colorectal Cancer, Head and Neck Cancer, Urinary Tract Cancer

FDA Approves Lenvima (lenvatinib) for the Treatment of Patients with Advanced Renal Cell Carcinoma in Combination with Everolimus Following Prior Anti-Angiogenic Therapy

Posted 16 May 2016 by Drugs.com

WOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ – Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an anti-angiogenic therapy. This approval was based on the impressive results of the registration study (Study 205), in which the once daily combination of 18 mg Lenvima and 5 mg everolimus demonstrated a substantial improvement in progression-free survival (PFS), powerful objective response rate (ORR) and clinically meaningful overall survival (OS) when compared with everolimus alone, a standard of care for patients with aRCC who have received prior anti-angiogenic therapy. "Lenvatinib plus everolimus is the first and only FDA-approved ... Read more

Related support groups: Renal Cell Carcinoma, Lenvima, Lenvatinib

Could Talk Therapy Ease Chemo-Related Memory Issues?

Posted 2 May 2016 by Drugs.com

MONDAY, May 2, 2016 – A type of psychotherapy might help cancer survivors deal with the long-term thinking problems some experience after chemotherapy, researchers say. It's estimated that about half of those who undergo chemotherapy for cancer develop what's often called "chemo brain." For instance, they may have trouble following conversations or remembering the steps in a project, according to background notes with the new study. Although usually mild, these changes can affect quality of life, job performance and relationships, said the researchers from the Eastern Maine Medical Center and Lafayette Family Cancer Center in Bangor, Maine. The researchers developed a cognitive-behavioral therapy (CBT) program called Memory and Attention Adaptation Training to help cancer survivors prevent or manage these memory problems. Their study involved 47 breast cancer survivors who underwent ... Read more

Related support groups: Cancer, Methotrexate, Breast Cancer, Prostate Cancer, Fluorouracil, Gleevec, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Brain Tumor, Melanoma, Xeloda, Skin Cancer, Tasigna, Pancreatic Cancer, Ovarian Cancer, Endometrial Cancer, Hydroxyurea

Exelixis Announces FDA Approval of Cabometyx (cabozantinib) for Patients with Advanced Renal Cell Carcinoma

Posted 27 Apr 2016 by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 25, 2016-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved Cabometyx (cabozantinib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. RCC is the most common form of kidney cancer in adults. Cabometyx, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate in a phase 3 trial for patients with advanced RCC, robust and clinically meaningful improvements in all three key efficacy parameters — overall survival, progression-free survival and objective response rate. “With today’s announcement, patients with previously treated advanced kidney cancer now have a new option, the first and only approved product demonstrated to help patients live longer w ... Read more

Related support groups: Renal Cell Carcinoma, Cabometyx, Cabozantinib

Drug Seems to Extend Survival for Advanced Melanoma Patients

Posted 18 Apr 2016 by Drugs.com

MONDAY, April 18, 2016 – More than one-third of advanced melanoma patients were still alive five years after starting therapy with the cancer drug nivolumab (Opdivo), researchers are reporting. "In 2012, we saw some very promising early evidence that this drug could not only cause the regression of very advanced cancer in patients with melanoma, lung or kidney cancers that had not responded to other forms of therapy, but we also saw that these responses appeared to be very durable," said lead researcher Dr. Suzanne Topalian. She is a professor of surgery and oncology at Johns Hopkins University School of Medicine, in Baltimore. Opdivo was approved for the treatment of advanced melanoma by the U.S. Food and Drug Administration in 2014. The results of this follow-up study, funded by Bristol-Myers Squibb, which makes Opdivo, were to be presented Sunday at the American Association for ... Read more

Related support groups: Lung Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Melanoma, Small Cell Lung Cancer, Opdivo, Melanoma - Metastatic, Nivolumab, Wilms' Tumor

Certain Biopsy Method Tied to Better Outcomes After Kidney Cancer

Posted 10 Mar 2016 by Drugs.com

THURSDAY, March 10, 2016 – A type of lab test called a "core-needle biopsy," performed on tissue taken from a mass on a kidney, may be better for certain kidney cancer patients, new research suggests. The study involved people with a renal (kidney) cell carcinoma – the most common type of kidney cancer in adults. Researchers led by Dr. Rosaleen Parsons, of Fox Chase Cancer Center in Philadelphia, noted that incidence and death rates of the disease have climbed in recent decades. But they added that so-called "image-guided" core-needle biopsy of kidney masses is increasingly being used to determine the best treatment approaches for individual patients. In their study, Parsons' team researchers tracked outcomes for patients who collectively underwent 374 kidney mass biopsies between 1999 and 2015. Core-needle biopsy – meaning that a tiny amount of tissue is removed using a hollow ... Read more

Related support groups: Cancer, Renal Failure, Renal Cell Carcinoma, Chronic Kidney Disease, Diagnosis and Investigation

Is Type 1 Diabetes Linked to Raised Risk of Certain Cancers?

Posted 2 Mar 2016 by Drugs.com

TUESDAY, March 1, 2016 – Having type 1 diabetes may raise the risk of some cancers, but lower the risk of others, a new study suggests. A higher risk was seen for cancers of the stomach, liver, pancreas, endometrium, ovary and kidneys. But a reduced risk was seen for prostate and breast cancers, researchers reported. In type 1 diabetes, the body cannot produce the hormone insulin, which helps regulate blood sugar levels. People with type 1 diabetes must be treated with insulin to survive. The good news from this study, said researcher Sarah Wild, is that it doesn't seem that insulin treatment is responsible for an increased risk of some cancers, which has been a concern. "This pattern of cancer risk [seen in the study] is similar to that seen for people with type 2 diabetes and people who are overweight," said Wild, a professor of epidemiology at the University of Edinburgh in the ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Diabetes, Type 1, Renal Cell Carcinoma, Ovarian Cancer, Pancreatic Cancer, Diabetes Mellitus, Stomach Cancer, Wilms' Tumor

Targeted Drug Shows Promise Against Advanced Kidney Cancer

Posted 6 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 6, 2016 – A targeted cancer drug appears to be effective against advanced kidney cancer, although its side effects may keep it from becoming widely used, researchers report. The drug, cabozantinib, proved more effective across-the-board in kidney cancer patients than another targeted drug called everolimus, said lead researcher Dr. Bernard Escudier. He is chair of the genitourinary oncology committee at the Institut Gustave Roussy in Villejuif, France. Overall, cabozantinib provided "almost a 50 percent improvement in progression-free survival" over everolimus, Escudier said. Cabozantinib works by interrupting several different cellular processes that help cancer grow and spread, Escudier explained. Unfortunately, that widespread approach also creates worrisome toxic side effects, he added. "Based on this multi-targeted action, we have quite a lot of side effects. ... Read more

Related support groups: Cancer, Renal Failure, Renal Cell Carcinoma, Chronic Kidney Disease, Cabozantinib, Urinary Tract Tumors, Solid Tumors, Cometriq, Urinary Tract Cancer

FDA Approves Opdivo to Treat Metastatic Renal Cell Carcinoma

Posted 23 Nov 2015 by Drugs.com

November 23, 2015 – The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. “Opdivo provides an important therapy option for patients with renal cell carcinoma,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “It is one of few therapies that have demonstrated the ability to extend patients’ survival in treating this disease.” Torisel (temsirolimus), approved in 2007, is the only other FDA-approved therapy that has demonstrated overall survival in renal cell cancer. Renal cell carcinoma is the most common form of kidney cancer in adults and forms in the tissues of the kidney that make urine. The National Cancer Institute estimates 61,560 ... Read more

Related support groups: Renal Cell Carcinoma, Opdivo, Nivolumab

Page 1 2 3 4 Next

Ask a Question

Further Information

Related Condition Support Groups

Wilms' Tumor, Cancer

Related Drug Support Groups

Depo-Provera, Provera, medroxyprogesterone, Votrient, Tarceva, Avastin, Sutent, Afinitor, Nexavar, view more... Opdivo, capecitabine, PegIntron, pazopanib, sunitinib, nivolumab, sorafenib, everolimus, Depo-Provera Contraceptive, erlotinib, interferon alfa-2a, bevacizumab, Torisel, Lenvima, peginterferon alfa-2b, Inlyta, Proleukin, Cabometyx, depo-subQ provera 104, Roferon-A, cabozantinib, axitinib, temsirolimus, lenvatinib, aldesleukin, Amen, Curretab, Cycrin